Posts by Mike Mooney
Dear HelpLine: Comstock Grants
Dear HelpLine, We recently joined an FTD support group, which has been so helpful. The support group volunteer told us about AFTD’s Comstock Grants. Can you help us learn more?…
Read MoreAdvancing Hope; AFTD Attends the Tau Global Conference
In late April, AFTD Research team members attended a premier conference focused exclusively on research into tau, a protein which is aggregated in Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS),…
Read MoreBrain Pathology Consistent with FTD Found in Roughly 35% of Motor Neuron Disease Cases in Recent Study
According to a recent study published in the research journal Brain, brain pathology consistent with FTD was detected in roughly 35% of the participants with motor neuron disease, which includes…
Read MoreFTD Science Digest: Help Advance Science by Joining the Updated FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than…
Read MoreFTD Research Spotlight: A New Researcher Portal and Other Updates from the FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than…
Read MoreThe Lived Experience of FTD: The Challenges of July Fourth
The following article was written by former Persons with FTD Advisory Council member Cindy Odell. The Council works to ensure the voice of people living with FTD guides AFTD as…
Read MoreChinese Study Explores the Psychological Well-being and Health of Dementia Caregivers
A study published in the journal BMC Geriatrics explores the self-assessed well-being of informal care partners and professional caregivers who support people with dementia, such as FTD. The study provides…
Read More“Alzheimer’s & Dementia” Publishes Summary of AFTD’s 2022 Holloway Summit
Digital health technologies have the potential to benefit the FTD community by improving accessibility to research and clinical care. Such technologies were the focus of the 2022 Holloway Summit —…
Read MoreVesper Bio Clinical Trial for FTD-GRN Treatment Achieves Enrollment Milestone
Danish biotechnology company Vesper Bio announced that it reached a participation milestone in its phase Ib/IIa clinical trial evaluating a treatment for FTD-GRN. Six participants have been enrolled in the…
Read MoreAdvancing Hope: Blood Test for Diagnosing Alzheimer’s Disease Approved by FDA
The United States Food and Drug Administration (FDA) approved the marketing of a blood test to diagnose Alzheimer’s disease. The test, known as the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain) 
English